FDA holds hearing on psychedelic therapy regulation and infrastructure

The U.S. Food and Drug Administration (FDA) recently held a four-hour hearing featuring over 80 speakers to discuss the implementation of psychedelic therapies in regulated settings. The discussions highlighted a growing consensus among regulators, physicians, and patient advocates regarding the potential of these treatments to address mental health crises, such as treatment-resistant depression and PTSD.

While clinical evidence, including studies from the New England Journal of Medicine and Oregon Health & Science University, supports the efficacy of substances like psilocybin, experts noted a significant gap in the necessary operational infrastructure. Discussions centered on creating a phased, evidence-based framework that includes certified treatment sites, regulated supply chains, mandatory safety standards, and accountable clinicians to ensure safe and scalable delivery.

Organizations such as SSDP participated in the hearing to advocate for responsible movement toward these therapies. Key points of debate included the specific requirements for therapy, the qualifications of facilitators, and how to expand access beyond hospital settings without compromising public health or entrenching exclusion.